| Literature DB >> 34265800 |
Stefanie Glöss1,2, Philipp Jurmeister3,2, Anne Thieme1,2,4, Simone Schmid1,2, Wei Y Cai5, Rene N Serrette5, Sven Perner6, Julika Ribbat-Idel6, Axel Pagenstecher7, Hendrik Bläker3,8, Ursula Keber7, Christine Stadelmann9, Sabrina Zechel9, Pascal D Johann10,11, Martin Hasselblatt12, Werner Paulus12, Christian Thomas12, Hildegard Dohmen13, Daniel Baumhoer14, Stephan Frank15, Abbas Agaimy16, Ulrich Schüller17,18,19, Varshini Vasudevaraja20, Matija Snuderl20,21, Cheng Z Liu20, David G Pfister22, Achim A Jungbluth5, Ronald A Ghossein5, Bin Xu5, David Capper1,4, Snjezana Dogan5.
Abstract
IDH2 R172 mutations occur in sinonasal undifferentiated carcinoma (SNUC), large-cell neuroendocrine carcinoma (LCNEC), sinonasal adenocarcinomas, and olfactory neuroblastoma (ONB). We performed a clinical, pathologic, and genetic/epigenetic analysis of a large IDH2-mutated sinonasal tumor cohort to explore their distinct features. A total 165 sinonasal/skull base tumors included 40 IDH2 mutants studied by light microscopy, immunohistochemistry, and genome-wide DNA methylation, and 125 IDH2 wild-type tumors used for comparison. Methylation profiles were analyzed by unsupervised hierarchical clustering, t-distributed stochastic neighbor embedding dimensionality reduction and assessed for copy number alterations (CNA). Thirty-nine histologically assessable cases included 25 (64.1%) SNUC, 8 (20.5%) LCNEC, 2 (5.1%) poorly differentiated adenocarcinomas, 1 (2.7%) ONB, and 3 (7.7%) IDH2-mutated tumors with ONB features. All cases were high-grade showing necrosis (82.4%), prominent nucleoli (88.9%), and median 21 mitoses/10 HPFs. AE1/AE3 and/or CAM 5.2 were positive in all and insulinoma-associated protein 1 (INSM1) in 80% cases. All IDH2 mutants formed one distinct group by t-distributed stochastic neighbor embedding dimensionality reduction separating from all IDH2 wild-type tumors. There was no correlation between methylation clusters and histopathologic diagnoses. Recurrent CNA included 1q gain (79.3%), 17p loss (75.9%), and 17q gain (58.6%). No CNA differences were observed between SNUC and LCNEC. IDH2 mutants showed better disease-specific survival than SMARCB1-deficient (P=0.027) and IDH2 wild-type carcinomas overall (P=0.042). IDH2-mutated sinonasal tumors are remarkably homogeneous at the molecular level and distinct from IDH2 wild-type sinonasal malignancies. Biology of IDH2-mutated sinonasal tumors might be primarily defined by their unique molecular fingerprint rather than by their respective histopathologic diagnoses.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34265800 PMCID: PMC8373679 DOI: 10.1097/PAS.0000000000001697
Source DB: PubMed Journal: Am J Surg Pathol ISSN: 0147-5185 Impact factor: 6.298